Matching Asthma Biologics to Patients Using Biomarkers Instead of Trial and Error
A review of blood eosinophils, FeNO, IgE and emerging omics and digital markers shows how to pick the right asthma biologic and move toward remission.
Riepilogo
Six biologic drugs are approved for moderate-to-severe asthma, but choosing among them is often trial and error, which delays control, adds cost and exposes patients to side effects. This review explains how biomarkers can guide that choice. Blood eosinophil count, exhaled nitric oxide (FeNO) and total IgE are the established tools for spotting type 2-high asthma, and each drug has its own useful cutoffs. Sputum tests give a direct look at airway inflammation but are available mainly at expert centers. Newer markers, including proteins, gene expression, metabolites, genetic variants, wearable and electronic-record data, and socioeconomic measures, may sharpen decisions further. No single test is perfect, so combining several is the likely path to better selection, monitoring and, ultimately, asthma remission. People with non-type 2 asthma still lack validated markers.
Riepilogo Dettagliato
Asthma is a chronic lung disease with many underlying inflammatory patterns, characterized by airway inflammation, hyperresponsiveness and reversible airflow obstruction. Biologic drugs that block specific inflammatory pathways have transformed care for moderate-to-severe disease, yet clinicians often choose among them by trial and error. That approach delays control, raises costs and exposes patients to avoidable side effects. This narrative review by Chiarella and colleagues summarizes the evidence on established and emerging biomarkers for picking the right biologic.
Six biologics are FDA-approved: omalizumab (anti-IgE), mepolizumab, reslizumab and benralizumab (anti-IL-5 pathway), dupilumab (anti-IL-4/IL-13) and tezepelumab (anti-TSLP). Blood eosinophil count is the most used predictor. Omalizumab works better at 260 cells/µL or higher. Mepolizumab cut exacerbations 52% at 150 or higher, with greater benefit at 500 or higher. Reslizumab benefits appeared at 400 or higher. Benralizumab trials used 300 or higher but it also works at 150 or higher. Dupilumab is used at 150 or higher, with more effect at 300 or higher. Tezepelumab is indicated regardless of count.
Fractional exhaled nitric oxide is a noninvasive marker of type 2 airway inflammation. Omalizumab patients with FeNO of 19.5 ppb or higher had greater exacerbation reductions, and FeNO screening cut per-patient cost by almost 50% in one study. Dupilumab and tezepelumab showed reductions at 25 ppb or higher, while FeNO was less useful for mepolizumab. Baseline total IgE is mainly used for omalizumab dosing and predicts response poorly. In a 25-patient study, a 4-week-to-baseline IgE ratio of 2 or higher had 100% sensitivity and 80% specificity. Sputum eosinophils above 3% predict anti-IL-5 response. Sputum neutrophilia is associated with T2-low disease, in which most biologics are generally ineffective.
Emerging markers include periostin. In the EXTRA study, high-periostin patients (over 50 ng/mL) had a 30% exacerbation reduction on omalizumab versus 3% in low-periostin patients. Plasma proteomic ratios (CXCL10/CCL17 for omalizumab, IL-13/TNF-α for mepolizumab) outperformed eosinophils and IgE. Transcriptomic work showed omalizumab responders shifting toward healthy-control gene profiles, and single-cell RNA sequencing showed fewer IL1B+ classical monocytes and NF-kB suppression. Metabolomic signals involved androgenic, carnitine and bile acid metabolites, and genetic variants such as ZNF415 rs1054485-T were linked to response. Digital biomarkers from electronic records, language-processing algorithms and wearables are being explored, as is the HOUSES socioeconomic index.
The authors stress that BEC and FeNO overlap across type 2 therapies, reducing specificity, and that levels fluctuate with disease activity, comorbidities and corticosteroid use. Many emerging markers lack validation, cost and access limit assays, and T2-low asthma still lacks validated markers. Future work should identify when to stop or resume biologics as remission becomes a goal, likely using AI to integrate multiple markers over time.
Risultati Principali
- Mepolizumab cut exacerbations 52% in patients with blood eosinophils of 150 cells/µL or higher, with greater benefit at 500 or higher
- Omalizumab worked better at eosinophils of 260 cells/µL or higher and FeNO of 19.5 ppb or higher
- FeNO screening for likely omalizumab response lowered per-patient cost by almost 50%
- Periostin above 50 ng/mL predicted a 30% omalizumab exacerbation reduction versus 3% with low periostin (EXTRA)
- A 4-week/baseline IgE ratio of 2 or higher predicted omalizumab response with 100% sensitivity and 80% specificity in 25 patients
- Plasma ratios CXCL10/CCL17 and IL-13/TNF-α predicted omalizumab and mepolizumab response better than eosinophils or IgE
- Sputum eosinophils above 3% predict response to anti-IL-5 therapies, while tezepelumab is indicated regardless of eosinophil count
Metodologia
This is a narrative review, not a systematic one, so no formal search protocol, pooled analysis or risk-of-bias assessment is described. It synthesizes randomized trial secondary analyses and smaller observational and omics studies. Evidence quality varies widely, from large phase III post hoc analyses to a 25-patient IgE study.
Limitazioni dello Studio
The authors note that BEC and FeNO overlap across type 2 therapies and fluctuate with disease activity, comorbidities and steroid use. Many emerging biomarkers are unvalidated, some studies characterize severity rather than predict drug response, and assay cost and access limit adoption. T2-low asthma lacks validated markers. No conflicts of interest are stated in the supplied text.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti:
